Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
Public ClinicalTrials.gov record NCT02605122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia
Study identification
- NCT ID
- NCT02605122
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Enrollment
- 97 participants
Conditions and interventions
Conditions
Interventions
- Solithromycin Drug
- Standard of Care Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Months to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2016
- Primary completion
- Mar 20, 2018
- Completion
- Mar 20, 2018
- Last update posted
- Jan 2, 2019
2016 – 2018
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 72202 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | Washington D.C. | District of Columbia | 20010 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Omaha | Nebraska | 68198-2162 | — |
| Not listed | Las Vegas | Nevada | 89102 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Greenville | North Carolina | 27834 | — |
| Not listed | Toledo | Ohio | 43606 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Hershey | Pennsylvania | 17033 | — |
| Not listed | Memphis | Tennessee | 38105 | — |
| Not listed | Amarillo | Texas | 79106 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Splendora | Texas | 77372 | — |
| Not listed | Charlottesville | Virginia | 22905 | — |
| Not listed | Richmond | Virginia | 29298 | — |
| Not listed | Roanoke | Virginia | 24013 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02605122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 2, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02605122 live on ClinicalTrials.gov.